The association between NfL and Cognitive Functioning in older adults diagnosed diabetes: a cross-sectional analysis from NHANES - LiLi; Li, Cheng-Bo; Zhu, Li; Zhu, Jiang (medRxiv, 2024)
Objective This research aimed to explore the correlation between serum Neurofilament Light Chain (NfL) levels and Cognitive Function in diabetic participants.Methods Utilizing cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) 2013 to 2014, 173 individuals aged 60 years and above with diabetes were included in the analysis. Cognitive function was measured using the Animal Fluency exercise. Weighted multivariate linear regression analysis and a restricted cubic spline model were employed to assess the association between serum NfL levels and Animal Fluency Score (CFDAST) in diabetic patients.Results Serum NfL was categorized into weighted tertiles, with participants divided into groups Q1, Q2, and Q3. Significant differences in serum NfL were observed among the groups (P < 0.01). Participants in group Q3 exhibited higher levels of hemoglobin A1c and were older compared to groups Q1 and Q2 (P < 0.01). Furthermore, when serum NfL was treated as a continuous variable, it was found to have a negative correlation with CFDAST score (P < 0.01). Group Q1 had a higher CFDAST score than group Q3, as well as group Q2 (p for trend = 0.0021). A nonlinear relationship was observed between serum NfL and CFDAST score, displaying an inverted ‘U-shaped’ curve (P-overall = 0.01, P-for-non-linear = 0.0026).Conclusions Serum NfL has the potential to serve as a clinical biomarker for early detection of cognitive impairment in diabetic individuals aged over 60 years.Highlights Study about biomarkers for diabetes-associated cognitive decline is limited.We found that there is an inverted U-shaped association between serum NfL and cognitive score.Serum NfL may be a biomarker for early detection of cognitive decline in elderly diabetics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:You can find related information from website:https://www.cdc.gov/nchs/nhanes/irba98.htm and website: https://www.cdc.gov/nchs/nhanes/genetics/genetic_participants.htm.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data files are available from the NHANES database https://www.cdc.gov/nchs/nhanes/index.htm?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fnchs%2Fnhanes.htm